Health Care · Services-Medical Laboratories

NTRA Natera Inc SEC Filings & Insider Trading Activity 2026

company
CIK 1604821187 filings

NTRA at a glance

Natera Inc (NTRA, SEC CIK 1604821) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Natera Inc (NTRA) reported revenue of $2.3 billion (up 35.9% from FY2024) and a net loss of $208.2 million. Diluted EPS was -$1.52.
  • As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Natera Inc (NTRA) shares worth $25.5 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Sheena Jonathan on November 11, 2026 of 40 shares at $315.26 per share.
  • In the last 90 days, NTRA insiders reported 0 open-market purchases ($0) and 177 open-market sales ($104.8M) on Form 4, a net sale of $104.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.3B
+35.9% vs prior year
Insiders · 90 days
0 buys · 177 sells
Net −$104.8M
13F holders
38 funds
$25.5B · −3 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes reported from the December 31, 2025 Form 10-K
  • Carried-forward business risk: disclosed 10-K risks could materially adversely affect operations and prospects
  • Market risk: adverse developments could reduce common-stock price and investor returns
  • Disclosure risk: additional unknown or currently immaterial risks could materially harm results

Management Discussion & Analysis

  • Quarterly revenue $794.0M, up 34.1% YoY from $592.2M
  • Product revenue $790.0M, up 33.9%; oncology units 339,500 vs 211,000
  • Product cost margin 64.6% vs 64.9% YoY, with net loss $59.9M vs $87.5M
  • Cash $1.1B; operating cash flow $138.9M, down from $141.4M; capital spending $124.2M
  • Outlook: continued net losses, heavy R&D investment, potential need for additional equity or debt financing

AI summary of the NTRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 5, 2026
  • Investor presentation furnished alongside earnings release, providing supplemental operating and financial detail

Item EX-99.2: Item EX-99.2

  • Q3 2026 revenue $794.0M, up ~34% year over year, with total tests exceeding 1.09M
  • Clinical MRD oncology volume ~316K, up >56% year over year and ~33K sequentially

Item EX-99.1: Item EX-99.1

  • Q3 revenue $794.0M, up 34.1% YoY, with reported tests up 23.0% to 1,024,800
  • Oncology tests 339,500, up 60.9% YoY, while clinical MRD units grew 32,700 sequentially
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced on August 6, 2026
  • Investor presentation accompanying earnings release, providing additional operating and financial context

Item EX-99.1: Item EX-99.1

  • Q2 revenue $752.8M, up 37.7% YoY, driven by higher testing volume and average selling prices
  • Tests processed 1,043,900, up 22.4%, with oncology tests up 57.2% to 296,700

Item EX-99.2: Item EX-99.2

  • Q2 2026 revenue $752.8M, up ~38% year over year, with total tests exceeding 1.04M
  • Clinical MRD oncology volume ~283K, up >56% year over year and ~34K sequentially, supporting Signatera growth
Filed Jul 6, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Monica Bertagnolli resigned as Natera director and committee member effective July 1, 2026
  • Departure tied to her new National Academy of Medicine position, not disagreement with Natera

AI summaries of NTRA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NTRA

Don't miss the next NTRA filing

  • Alerts as it files. A push when NTRA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NTRA, by share count.
  • Ask anything. An AI agent that reads every NTRA filing and answers with sources.

NTRA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Sheena JonathanSellNov 11, 2026$315.26
Sheena JonathanSellNov 11, 2026$316.93
Sheena JonathanSellNov 11, 2026$317.87
Sheena JonathanSellNov 11, 2026$319.77
Sheena JonathanSellNov 11, 2026$320.02
Sheena JonathanSellNov 11, 2026$322.00
Sheena JonathanSellNov 11, 2026$323.06
Sheena JonathanSellNov 11, 2026$315.28

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$1.7B$2.3B
Operating Income--$222.3M-$309.9M
Net Income-$434.8M-$190.4M-$208.2M
Op. Margin--13.1%-13.4%
Net Margin--11.2%-9.0%
Balance Sheet
Total Assets-$1.7B$2.4B
Equity$765.3M$1.2B$1.7B
ROE-56.8%-15.9%-12.2%
Per Share
EPS-$-1.53$-1.52
Cash Flow
Operating CF-$247.0M$135.7M$215.3M
CapEx$39.2M$66.4M$106.2M

Source: XBRL data in Natera Inc (NTRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NTRA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NTRA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202638$25.51B
Q2 202641$19.08B
Q1 202640$13.43B
Q4 202538$14.73B
Q3 202537$12.77B
Q2 202535$11.46B
Q1 202533$5.92B
Q4 202430$4.97B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 292 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NTRA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
4Nov 10, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Oct 30, 2026--
4Oct 29, 2026--
4Oct 29, 2026--
4Oct 29, 2026--
4Oct 29, 2026--
4Oct 29, 2026--
4Oct 29, 2026--
4Oct 29, 2026--
4Oct 23, 2026--
4Oct 20, 2026--
4Oct 16, 2026--
4Oct 9, 2026--
4Oct 2, 2026--
4Oct 2, 2026--

Related Health Care companies

All Health Care →

NTRA SEC filings: frequently asked questions

Are NTRA insiders buying or selling?

In the last 90 days, Natera Inc (NTRA) officers, directors and 10% owners reported no open-market purchases and 177 open-market sales worth $104.8 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold NTRA stock?

As of September 30, 2026, the largest Natera Inc (NTRA) holders among the 13F filers tracked by SignalX were JPMorgan Chase & Co ($5.8 billion), BlackRock ($4.4 billion), T. Rowe Price Group ($2.8 billion), Vanguard Capital Management LLC ($2.6 billion), Vanguard Portfolio Management LLC ($2.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NTRA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Natera Inc (NTRA) reported revenue of $2.3 billion (up 35.9% from FY2024) and a net loss of $208.2 million. Diluted EPS was -$1.52. The figures come from the XBRL data in the 10-K.

What did NTRA report in its latest 8-K?

Natera Inc (NTRA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for quarter ended September 30, 2026 announced November 5, 2026.

What are the latest NTRA SEC filings?

Natera Inc (NTRA) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is NTRA's SEC CIK number?

Natera Inc (NTRA)'s SEC Central Index Key (CIK) is 1604821. EDGAR lists every NTRA filing under that number.

Ask anything about NTRA

The research agent reads NTRA's filings, financials, insider trades and 13F holders, then answers with sources.